Cancer diagnosis used to hinge almost entirely on the trained eye of a radiologist or pathologist, working scan by scan, slide by slide. That model is now being layered — not replaced, but sharpened — by algorithms that can flag a suspicious lesion in milliseconds or predict a chemotherapy dose from a CT scan's fat, bone, and muscle composition. That shift is exactly what's fueling...

The Anti-Neoplastic Agents Market is undergoing significant transformation as pharmaceutical innovation, advances in oncology, and increasing cancer prevalence drive demand for effective therapeutic solutions. Anti-neoplastic agents encompass medicines used to prevent, inhibit, or control the growth and spread of cancer cells. The evolving oncology landscape is encouraging pharmaceutical...

The global industry was valued at US$ 140.2 Bn in 2022 and is estimated to grow at a CAGR of 9.1% from 2023 to 2031, reaching US$ 303.1 Bn by the end of 2031. The anticancer drugs market is witnessing substantial expansion as the global burden of cancer continues to rise and healthcare systems increasingly prioritize advanced oncology treatments. The growing prevalence of various forms of...

The global Cancer Diagnostics Market is expanding as healthcare providers increasingly invest in liquid biopsy, next-generation sequencing, molecular assays, digital pathology, and early-detection platforms to improve accuracy and support precision oncology. According to Business Market Insights, the Cancer Diagnostics Market size was valued at US$ 18.62 Billion in 2025 and is projected to...

Polaris Market Research has released its latest research report on the Cancer Gene Therapy market, offering a comprehensive view of the current market landscape and its future outlook. The report examines the major forces driving growth, including rising demand, evolving technology, expanding applications, investment flows, and competitive dynamics. It provides insight into how the market...

The global industry was valued at US$ 1.6 Bn in 2022 and is estimated to grow at a CAGR of 6.8% from 2023 to 2031, reaching US$ 2.9 Bn by the end of 2031. The head and neck cancer market is witnessing significant growth due to the rising prevalence of cancer cases, increasing awareness regarding early diagnosis, and advancements in targeted therapies and immunotherapy treatments. Head and neck...

The increasing demand for oncology therapeutics market solutions, rising adoption of cancer treatment drugs, and rapid advancements in targeted cancer therapies are transforming the global cancer treatment landscape. With the growing prevalence of head and neck cancers, healthcare providers and pharmaceutical companies are focusing on developing innovative therapies...

The global immunotherapy drugs market was valued at USD 285.7 billion in 2025 and is projected to reach USD 676.0 billion by 2033, growing at an 11.4% CAGR from a 2026 base of USD 317.2 billion. Monoclonal antibodies account for 56.16% of drug-type revenue; cancer indications account for 88.42% of the market. North America leads with 41.8% share; Asia Pacific is the fastest-growing...

Liquid biopsies are no longer limited to cancer diagnosis—their applications in oncology now span early detection, treatment monitoring, and minimal residual disease (MRD) tracking, making them indispensable tools for personalized care. By analyzing circulating tumor DNA (ctDNA) and other biomarkers in blood, these tests provide real-time insights into tumor behavior, enabling clinicians...

"Executive Summary Next-Generation Targeted Oncology Drug Market Size and Share Analysis Report CAGR Value The global Next-Generation Targeted Oncology Drug Market research report has incorporated the analysis of different factors that augment the market's growth. It has various sections that provide the scope of different segments and applications that can potentially influence the market...

The rapid evolution of cancer molecular diagnostics, increasing adoption of molecular diagnostics in oncology, and growing demand for precision oncology diagnostics are transforming cancer detection and treatment worldwide. Molecular diagnostic technologies enable healthcare professionals to identify genetic mutations, biomarkers, and tumor-specific molecular...

"In-Depth Study on Executive Summary Oral HER Pathway Targeted Drugs Market Size and Share CAGR Value The global oral HER pathway targeted drugs market size was valued at USD 6.24 billion in 2025 and is expected to reach USD 15.01 billion by 2033, at a CAGR of 11.60% during the forecast period The Oral HER Pathway Targeted Drugs Market report contains...

The cancer biomarkers market is entering a period of strong expansion as rising cancer cases, increasing emphasis on early diagnosis, and growing adoption of personalized treatment continue to reshape oncology care. According to Grand View Research, the market size was valued at USD 26.9 billion in 2025 and is projected to increase from USD 29.9 billion in 2026 to USD 65.3 billion by 2033,...

The AI in oncology market is entering a rapid expansion phase as healthcare providers, researchers, and pharmaceutical companies increasingly use artificial intelligence to improve cancer diagnostics, treatment planning, and research. The market was valued at USD 6.0 billion in 2025 and is projected to grow from USD 8.3 billion in 2026 to USD 38.9 billion by 2033, registering a CAGR of 24.8%...

The nuclear medicine market is entering a period of steady expansion as healthcare systems increasingly adopt precision diagnostics and targeted therapies. The market was valued at USD 21.3 billion in 2025 and is projected to reach USD 38.2 billion by 2033, growing at a 6.8% CAGR from 2026 to 2033. The market is estimated to reach USD 24.1 billion in 2026. Growth is being supported by a robust...